Eupraxia Ppharmaceuticals Archives

ive professionals meet around a conference table with laptops and calendars, beside a whiteboard highlighting December EoE data and EPRX.

Eupraxia: A Packed Investor Calendar Sets the Table for December EoE Data -( $EPRX $IBB $REGN $SNY $TAK $XBI )

by John F. Heerdink, Jr. 3 days ago 238Views 0Likes

With its 120-patient target reached, encouraging early durability data and a November investor calendar, Eupraxia Pharmaceuticals is building a more substantial case for long-acting drug delivery. Eupraxia Pharmaceuticals (NASDAQ: EPRX; TSX: EPRX) is approaching the kind of stretch that can move a…

The Million‑Patient Question: Is Eupraxia’s EP‑104GI Ready To Turn EoE Endoscopy Into A Business Model? -( $EPRX $SNY $XBI )

by John F. Heerdink, Jr. July 30, 2026 325Views 0Likes

Eupraxia Pharmaceuticals (NASDAQ: EPRX) wrapped up its KOL event today with a clear message for Wall Street and the GI community: EP‑104GI is not just another esophageal steroid, it is being architected to live comfortably inside real‑world upper endoscopy practice for eosinophilic…

Wall Street On A Good Trip: Lilly, CareDx, And Eupraxia Rewrite The Biotech Script -( $ATAI $CDNA $EPRX $LLY )

by John F. Heerdink, Jr. July 16, 2026 481Views 0Likes

Biotech’s latest plot twist has Wall Street grinning: a Big Pharma icon betting billions on psychedelics, a transplant diagnostics player finally getting its Medicare script approved, and a quietly ambitious drug-delivery innovator upgrading its cast of characters for the next act. Lilly’s…

Tag: Eupraxia Ppharmaceuticals

Eupraxia: A Packed Investor Calendar Sets the Table for December EoE Data -( $EPRX $IBB $REGN $SNY $TAK $XBI )

The Million‑Patient Question: Is Eupraxia’s EP‑104GI Ready To Turn EoE Endoscopy Into A Business Model? -( $EPRX $SNY $XBI )

Wall Street On A Good Trip: Lilly, CareDx, And Eupraxia Rewrite The Biotech Script -( $ATAI $CDNA $EPRX $LLY )

Your Guide To Staying Informed In The Markets